Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

European journal of cancer (Oxford, England : 1990) - 1 Feb 2021

Yoshida Hironori, Nomizo Takashi, Ozasa Hiroaki, Tsuji Takahiro, Funazo Tomoko, Yasuda Yuto, Ajimizu Hitomi, Yamazoe Masatoshi, Kuninaga Kiyomitsu, Ogimoto Tatsuya, Hosoya Kazutaka, Itotani Ryo, Sakamori Yuichi, Kim Young Hak, Hirai Toyohiro

Abstract excerpt

BACKGROUND: We previously reported that PD-L1 polymorphisms are associated with the efficacy and immune-related adverse events of PD-1 blockade with nivolumab. However, the association between PD-L1 polymorphisms and survival outcomes under PD-1/PD-L1 blockade is still uncertain. Here, we aimed to investigate whether PD-L1 polymorphisms are associated with survival outcomes in advanced non-small-cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Follow-Up Studies

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Prognosis

Share to Survival Rate

Source

Identifiers

PMID: 33385948
DOI: 10.1016/j.ejca.2020.11.035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.PMID 33385948Read ↗

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.Semantic proximity Read ↗

Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.Semantic proximity Read ↗

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLCSemantic proximity Read ↗

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.Semantic proximity Read ↗

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.Semantic proximity Read ↗

Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.Semantic proximity Read ↗

The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-AnalysisSemantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.Semantic proximity Read ↗

Shedding light on the molecular determinants of response to anti-PD-1 therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.